LOT ONE RESEARCH — Educational Reference Deck
This deck is compiled for educational and informational purposes.
Tesamorelin is a prescription pharmaceutical. Research-grade material is not approved for human use.
Decisions about any hormone-axis compound belong between an individual and a licensed physician.
Tesamorelin is a synthetic form of growth hormone releasing hormone (GHRH). It is a 44 amino acid peptide matching the full sequence of the body's natural GHRH molecule, with one modification: a trans-3-hexenoic acid group attached to the tyrosine at the front end of the chain.
That modification protects the peptide from DPP-4, the enzyme responsible for natural GHRH lasting only about two minutes in the bloodstream.
Developed by Theratechnologies, Inc. of Canada. Approved in 2010 under the brand name Egrifta for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. An updated formulation, Egrifta WR, was approved in 2024 allowing weekly reconstitution instead of daily.
Now used off label for body recomposition and anti-aging. Requires a prescription in pharmaceutical form. Prohibited by WADA under Peptide Hormones, Growth Factors, and Related Substances.
Tesamorelin gets called the visceral fat peptide. It does not specifically target visceral fat.
The reputation exists because the clinical trials measured visceral fat reduction using CT scans, and that is the endpoint that earned the approval.
The mechanism is identical to CJC-1295 and Sermorelin. Same pathway, same receptor, same downstream cascade.
The difference is in what was measured, not in what the peptide does. If CJC-1295 had been put through a 26-week visceral fat study with CT scans, the data would likely look similar. That study was never funded because the company behind CJC was not pursuing an HIV lipodystrophy approval.
The hypothalamus produces GHRH. GHRH travels to the pituitary gland and signals it to release growth hormone.
The body has a second signal working alongside it. The stomach produces ghrelin, which amplifies the GHRH signal.
When GHRH and ghrelin are both active at the same time, the growth hormone pulse is much larger than either signal alone.
This is why the biggest natural GH pulses happen during deep sleep in a fasted state — both signals are firing together.
Growth hormone travels to the liver, where it is converted into IGF-1 (insulin-like growth factor 1). IGF-1 does most of the downstream work: fat mobilization, muscle protein synthesis, recovery, collagen production, bone density maintenance.
The liver needs insulin present to efficiently convert GH into IGF-1. Without insulin, growth hormone circulates but does not convert well.
Best GH release happens fasted (low insulin, high ghrelin). Best IGF-1 production happens fed (insulin present for liver conversion).
Sleep fasted, get a large overnight GH pulse. Wake up, eat, insulin rises, the liver converts circulating GH into IGF-1, and that IGF-1 works throughout the day.
Tesamorelin binds GHRH receptors on somatotroph cells in the anterior pituitary, mimicking the natural hypothalamic GHRH signal. It tells the pituitary to release the body's own growth hormone.
This maintains natural feedback loops, preserves the pulsatile release pattern, and is considered safe for long-term use.
But it only activates one pathway — the GHRH pathway. This is why GHRH analogs are commonly stacked with GHRPs like ipamorelin, which mimic the ghrelin pathway. Hitting both simultaneously produces a substantially larger pulse.
Unlike exogenous growth hormone injections, tesamorelin preserves pulsatility. The pituitary still responds to normal feedback, including inhibition by somatostatin, which acts as a brake. The body retains regulatory control rather than being overwhelmed by constant supraphysiologic doses.
Tesamorelin absorbs rapidly and clears fast, but the pituitary response to the signal lasts far longer than the peptide itself. The GH spike drives a gradual rise in IGF-1 over the following weeks.
Because the half-life is so short, daily dosing is required. The consistent daily signal is what keeps the GH/IGF-1 axis elevated.
Clinical trials demonstrate a reduction in visceral adipose tissue of approximately 15 to 20 percent over 26 weeks. A 2026 meta-analysis of five randomized controlled trials confirmed a visceral adipose tissue reduction of approximately 27.71 cm², along with a 1.18 kg decrease in trunk fat. This targets the deep abdominal fat most associated with cardiovascular and metabolic disease risk.
While reducing fat, tesamorelin preserves lean body mass. In the same meta-analysis, lean body mass increased by 1.42 kg. The fat loss is not coming at the expense of muscle — which matters during any caloric restriction or recomposition effort.
In the pivotal 412-patient trial, triglycerides dropped by about 50 mg/dL on average and the total cholesterol to HDL ratio improved significantly.
Research shows a reduction in hepatic fat content of approximately 37 percent relative to baseline in patients with nonalcoholic fatty liver disease. In a 2019 randomized trial, 35 percent of tesamorelin-treated participants reduced liver fat below the 5 percent threshold defining fatty liver, compared to 4 percent in placebo. Tesamorelin-treated participants were also significantly less likely to experience progression of liver fibrosis.
Working through the GHRH receptor maintains physiological feedback mechanisms, producing more natural GH pulsatility than direct growth hormone injections, which bypass the feedback system entirely.
Elevated GH and IGF-1 support collagen turnover, joint integrity, and soft tissue repair. Active individuals may experience improved training recovery and faster healing from minor injuries.
A 2025 clinical trial of 73 HIV-positive participants with abdominal obesity found a trend toward improved neurocognitive performance, though the difference between groups did not reach statistical significance. Earlier research suggested potential improvements in executive function and working memory, but the evidence remains preliminary and studied primarily in HIV-positive populations. More data is needed before drawing strong conclusions.
Some report improvements in sleep quality, though not everyone notices this early. The growth hormone signal is being established.
Recovery from training tends to improve as IGF-1 levels stabilizes. Typically when the compound starts to be felt before it can be seen.
Body composition changes become visible if diet and training are dialed in. Fat mobilization from elevated IGF-1 starts producing measurable results.
The most significant visceral fat reduction occurs in this window. Clinical trials showed the greatest reductions over a full 26-week protocol.
412 HIV-infected patients with abdominal fat accumulation. Participants received either 2 mg tesamorelin or placebo subcutaneously daily for 26 weeks.
Results: Visceral adipose tissue decreased 15.2 percent in the tesamorelin group and increased 5.0 percent in placebo. Triglycerides decreased 50 mg/dL. Total cholesterol to HDL ratio improved significantly. IGF-1 rose 81 percent into the mid-normal range. Lean body mass preserved. Glucose tolerance not worsened.
Context: These were patients with severe metabolic dysfunction from HIV-associated lipodystrophy. A safety extension followed patients for 12 months total, with continued users seeing visceral fat reductions of approximately 18 percent.
Multicenter, randomized, double-blind, placebo-controlled. Published in the New England Journal of Medicine (2007) and Journal of Acquired Immune Deficiency Syndromes (2010).
50 HIV-infected patients. Net treatment effect of −16.6 percent on visceral adipose tissue, plus modest reductions in liver fat with a net −2.9 percent reduction in hepatic lipid to water ratio. Published in JAMA.
Randomized, double-blind, multicenter trial of 61 participants with HIV and nonalcoholic fatty liver disease. Hepatic fat fraction reduced 37 percent relative to baseline. 35 percent of treated participants dropped liver fat below the 5 percent NAFLD threshold versus 4 percent in placebo. Fibrosis progression significantly less likely (10 percent vs 37 percent). Published in The Lancet HIV.
Five randomized controlled trials examining tesamorelin in HIV-associated lipodystrophy. Confirmed visceral adipose tissue reduction of 27.71 cm², trunk fat reduction of 1.18 kg, lean body mass increase of 1.42 kg, and hepatic fat decrease of 4.28 percent. No serious side effects or perturbation of glucose metabolism. Published in Obesity Research and Clinical Practice.
Phase 2 randomized open-label trial of 73 HIV-positive participants with abdominal obesity. Waist circumference reduced significantly, but cognitive benefits did not significantly differ between groups. IGF-1 increased but showed no correlation with cognitive improvements. Published in the Journal of Infectious Diseases.
All major clinical trials on tesamorelin were conducted in HIV-positive populations with lipodystrophy or NAFLD.
There are no large randomized controlled trials in otherwise healthy adults using tesamorelin for general body composition or anti-aging.
The mechanism supports these applications. The direct clinical evidence in healthy populations does not exist.
Read every efficacy number in this deck through that filter.
Aggregated from external platforms including Reddit, peptide forums, and clinic testimonials. This is anecdotal data and does not carry the weight of published research.
Users widely report noticeable reductions in abdominal circumference and waist measurement over 3 to 6 months, most consistently among those running the full 2 mg daily protocol. Some report improved muscle tone alongside fat loss. Lower doses and inconsistent protocols correlate with slower or less noticeable results.
Many report improved sleep quality within the first 2 to 4 weeks, and faster recovery between training sessions once IGF-1 stabilizes.
Injection site reactions dominate the discussion — redness, itching, and flushing lasting 10 to 20 minutes post-injection, significantly more common and intense than with CJC-1295 or ipamorelin. Conversely, users report the head rush and heart rate increase is much less prevalent than with CJC-1295.
The most discussed practical concern. At 2 mg daily, a 5 mg vial lasts 2.5 days — roughly 12 vials per month.
A large number of forum users report ruined vials from refrigerating reconstituted tesamorelin. The most common practical mistake, because it runs against standard handling for every other peptide.
The 2 mg daily dose comes directly from the FDA-approved prescribing information and is the dose used across all published clinical trials. No published dose-finding studies support lower doses for efficacy in visceral fat reduction.
Common off-label patterns: 3 to 6 months on, then 1 to 2 months off. Some anti-aging practitioners use continuous lower doses, but that approach is less studied.
The synergy between GHRH and GHRP only happens when both pathways are activated in the same window. GHRP suppresses somatostatin while GHRH drives pituitary output, and that combined signal produces a much larger growth hormone pulse than either alone.
Splitting them apart gives two smaller separate pulses, which defeats the purpose of stacking.
Injecting fasted before bed means low insulin and high ghrelin, maximizing the GH pulse. That GH circulates 2 to 3 hours overnight mobilizing fat. Breakfast raises insulin, the liver converts circulating GH into IGF-1, and that IGF-1 works all day.
If nighttime dosing disrupts sleep, switch to morning: inject fasted, wait at least 2 hours before eating. Both approaches are effective.
Subcutaneous, typically in the abdomen below the navel. Rotate sites to avoid scar tissue buildup. Do not inject into scarred, bruised, or irritated skin.
Store lyophilized vials refrigerated at 36–46°F (2–8°C). Can be stored in the freezer at −4°F (−20°C) for longer periods. Protect from light. Do not use past expiration.
Store at room temperature, 68–77°F (20–25°C). Do not refrigerate. Do not freeze. Use within 7 days. If the solution becomes cloudy, thickened, or gel-like, discard it.
Tesamorelin carries a synthetic modification on the front end that repels water, and the amino acid sequence itself is loaded with hydrophobic residues. When temperature drops, those regions on adjacent molecules bind to each other — that is what causes gelling.
This property is built into the sequence and exists in every vial regardless of manufacturer.
The FDA-approved version includes 145 mg of a stabilizer called hydroxypropyl betadex that wraps around the hydrophobic regions and prevents clumping. Research-grade tesamorelin is the same molecule but typically does not include this stabilizer. The room temperature requirement still applies because it relates to the physical properties of the molecule itself, but stability windows may differ.
If you have been refrigerating and the solution still looks clear: you have probably been finishing vials within a few days before aggregation becomes visible. That is outrunning the problem, not proving cold storage is safe.
Standard peptide purity testing measures chemical degradation — whether the amino acid chain is intact. Tesamorelin's issue is physical aggregation, molecules clumping in solution. A standard purity test will not detect it. Detecting it requires dynamic light scattering or size exclusion chromatography, which are not on a standard COA.
The most logical pairing. Tesamorelin activates the GHRH pathway, ipamorelin the ghrelin pathway. Together they produce a synergistic GH pulse significantly larger than either alone. Pin together, same window, fasted before bed.
No interaction concerns. Different mechanisms — angiogenesis and cell migration, not the GH axis. Can run concurrently. BPC-157 does not require fasting, so it can be injected any time while tesamorelin stays on its own fasting schedule.
No interaction concerns. Different mechanisms. Can run concurrently without timing conflicts. (Retatrutide, Semaglutide, Tirzepatide)
No interaction concerns. Can run alongside testosterone replacement therapy.
Do not combine with direct growth hormone injections. Exogenous GH triggers negative feedback through somatostatin, which suppresses the pituitary response to tesamorelin. Conflicting signals.
The mechanism is identical. All GHRH analogs signal the pituitary to release GH, GH raises IGF-1, IGF-1 mobilizes fat through lipolysis. There is no special visceral fat receptor. The difference is the clinical data, not the mechanism. The honest answer is we do not know, because the head-to-head study does not exist.
No. Temperature-dependent solubility inverts at cold temperatures and the hydrophobic regions bind into a gel. Once that happens the vial is finished.
Fasted, 30–60 minutes before bed or fasted in the morning at least 2 hours before eating. Bedtime aligns with natural GH production during deep sleep. Morning works for anyone whose sleep is disrupted by nighttime injection.
Trials used continuous daily dosing for 26 weeks. Common off-label protocols run 3 to 6 months on, 1 to 2 months off. No established evidence that cycling is necessary, but periodic breaks are considered reasonable.
No published dose-finding studies support lower doses for visceral fat reduction. 2 mg daily produced the results in every trial. There is no published evidence a lower dose produces comparable results.
The most commonly reported adverse events across clinical trials: injection site reactions (redness, swelling, pain, itching, flushing), arthralgia, myalgia, peripheral edema, and paresthesia. Injection site reactions are the most frequent, typically lasting 10 to 20 minutes post-injection.
The 2026 meta-analysis confirmed adverse events across five RCTs were limited to arthralgia, myalgia, paresthesia, and injection-site reactions, with no serious adverse effects and no perturbation of glucose metabolism.
Tesamorelin raises IGF-1, which is the intended effect but requires monitoring. A temporary increase in fasting glucose was observed at 2 weeks in one study but normalized by 6 months. Anyone already pre-diabetic or insulin resistant could theoretically see worsened blood sugar control. Trials monitored this closely and most healthy individuals did not have issues, but it warrants tracking.
Sleep disruption may require switching from nighttime to morning dosing. Carpal tunnel syndrome can occur related to fluid retention. Hypersensitivity reactions (rash, hives, difficulty breathing) are rare but require immediate discontinuation.
Not studied in children for this indication and not recommended under 18. Women should not breastfeed while using tesamorelin.
Every efficacy figure in this deck comes from 2 mg daily, uninterrupted, for 26 weeks. That is the input the outcomes were measured against. Here is what that input actually amounts to.
10 mg vial + 2 mL bacteriostatic water = 5000 mcg/mL. A 2 mg dose draws 40 units on an insulin syringe. Each vial covers 5 days.
Reconstituted tesamorelin holds 7 days at room temperature. At 2 mg daily a 10 mg vial is finished in 5 days, comfortably inside that window with no waste.
IGF-1 takes 2 to 4 weeks of consistent daily dosing to stabilize. An interruption does not just pause progress, it costs the re-stabilization window on the back end. A 26-week protocol acquired in monthly increments introduces six separate points of failure.
Running 1 mg alongside ipamorelin means a 10 mg vial holds 10 days of material but only 7 days of usable material — roughly 3 mg discarded per vial. 5 mg vials are the correct size for that protocol. No published trial validated 1 mg as a standalone visceral fat dose, so trial outcomes do not transfer to it.
Educational reference material.
Not medical advice. Not a treatment recommendation. Research use only.
Consult a licensed physician before making any decision involving hormone-axis compounds.
TESAMORELIN